Research Radboud technology centers Radboud Biobank News Pilot Broad Consent at the Gate
25 February 2020

The Blue Diamond Gallery

In line with the NFU initiative “Broad Consent at the Gate” (Breed Consent aan de Poort), the Radboud Biobank is currently conducting a feasibility study examining consent procedures for the use of residual material for scientific research. Residual material encompasses biomaterials leftover from standard clinical procedures, clinical imaging and medical data. The specific aim of this study is to evaluate the impact of implementing an active consent procedure (i.e. opt-in consent, which requires explicit consent) in place of the passive consent procedure currently used in the Radboudumc (i.e. opt-out consent, which requires explicit objection). Importantly, this study does not override the consent status of previously established research studies.
As of January 13, 2020, each new patient registering for the first time at the Radboudumc is actively asked for consent to use his/her residual biomaterial, clinical imaging and medical data for scientific research. To date, there has been no major organizational obstacles in the implementation of this new consent procedure. However, its impact on available material and data is still under evaluation. In addition to quantitative analyses, qualitative research exploring underlying motivations of patients who consent or do not consent to the use of their material and data will also be performed. This feasibility study will be further expanded to assess the impact of the new consent procedure on vulnerable patient groups, i.e. children (<16 years old), acute care patients, and incapacitated patients.   
For further information, please visit our website, “Use of medical data and leftover biomaterial”  (available in Dutch only), or contact Dr. Jennifer Lutomski, project leader, at Jennifer.Lutomski@radboudumc.nl.
 
  • Want to know more about these subjects? Click on the buttons below for more news.

    Radboud Biobank

Related news items


Dutch-Nordic Alliance for Precision Cancer Medicine launched

26 November 2021

The Nordic countries (Denmark, Sweden, Norway, and Finland) are together setting up national clinical precision cancer trials modelled on the very successful DRUP trial in the Netherlands.

read more

New Automated PBMC isolation method introduced in LMI.

21 September 2021

The Radboud Biobank (RB) and the laboratory of Medical Immunology (LMI) are making plans to replace the density gradient centrifugation method with a new automated PBMC isolation method, the AutoMACS Pro Separator.

read more

Health-RI, geared up to accelerate

21 September 2021

The Dutch cabinet has selected Health-RI's National Growth Fund proposal for a national health data infrastructure. On 5 October, the kick-off will take place during a live meeting in Jaarbeurs Media Plaza in Utrecht.

read more

SUNRISE-CRC sub-biobank

21 September 2021

The main purpose of SUNRISE-CRC is to determine whether treatment with a high dose of sunitinib provides a better chance of survival and slows the progression of (colo)rectal cancer (CRC) more than standard treatment with TAS-102.

read more

PRECISE sub-biobank

21 September 2021

The aim of the PRECISE biobank is to develop the first, smart multi-modal liquid biopsy test service for the prediction of immune checkpoint inhibitor response in urothelial cancer (UC) patients – the PRECISE IVD.

read more

Lysine Metabolism sub-biobank

21 September 2021

Hereditary metabolic disorders form a large group of more than 1,400 rare disorders in which an error in the DNA causes abnormalities in the process in which proteins, fats and carbohydrates are converted into smaller building materials and energy.

read more